| Name | Title | Contact Details |
|---|---|---|
Michael Holmes |
Senior Vice President and Chief Technology Officer | Profile |
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment.
Vector Laboratories Inc is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016. Linnaeus is based upon discoveries from the Ridky lab at the University of Pennsylvania.
Remel Inc is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.